Universal MRSA Screening – Is it Worthwhile, and For Whom
Dr. Barry Cookson, University College of London
A Webber Training Teleclass

Universal MRSA Screening
Is it worthwhile and for whom?

Professor Barry Cookson
Division of Infection and Immunity,
Univ. College London
Dept. of Health Policy,
London School of Hygiene & Tropical Medicine

Hosted by Paul Webber
paul@webbertraining.com

IT REALLY DOES DEPEND !!!!
“CONTEXT” is EVERYTHING
EXAMINE THE QUALITY OF THE EVIDENCE
DECIDE HOW APPLICABLE THE STUDY IS TO YOUR COUNTRY AND YOUR HOSPITAL
ENGAGE WITH ALL RELEVANT STAKEHOLDERS
ENSURING OWNERSHIP OF THE DECISIONS

Outline
1. Types of Screening:
   Focus on Admission Screening
2. Effectiveness of measures it informs?
3. Who are the Stakeholders?
4. Review of studies
5. Conclusions

MRSA a typical Healthcare Associated Infection Pathogen
The Iceberg Phenomenon

Bloodstream Infections
Other Infections
Colonisation (=70%)
Undetected Colonisation

Outline
1. Types of Screening:
   Focus on Admission Screening
2. Effectiveness of measures it informs?
3. Who are the Stakeholders?
4. Review of studies
5. Conclusions

Hosted by Paul Webber  paul@webbertraining.com
www.webbertraining.com
Universal MRSA Screening – Is it Worthwhile, and For Whom
Dr. Barry Cookson, University College of London
A Webber Training Teleclass

Modeling an Issue?
- George Box
  “Essentially all models are wrong but some are useful”
- Anderson and May 1991
  “mathematical models are no more and no less tools for thinking clearly about something.”
- Our Modelling group (BMJ discussion)
  “Use of models, combined with the empirical assessment of their findings, is the most realistic and viable approach”
  1) can help understand how different factors interact and affect success or failure of combinations of interventions
  2) especially where it is not feasible to use clinical studies alone.

Context is EVERYTHING!
Modeling SENSITIVITY analyses show huge influences of:
- MRSA occurrence (prevalence/incidence)
- MRSA “challenges” to the system e.g. re-admissions, Long Term Care Facility dynamics, CA-MRSA, LA-MRSA…
- Case mix; hospital type, transfer patterns inter ward/ICU (“carousel”)...
- Healthcare system e.g. private/public funded, patient advocates
- Other infection control interventions and effectiveness e.g. hand hygiene, decolonisation/suppression, isolation (ward/cohorts/single-bed rooms) AND
- When done e.g. before results, after risk assessment?……
(Study Design: EQUATOR www site for STROBE and CONSORT tools also ORION tools (Google “IDRN ORION”))

HTA MRSA Isolation: Systematic Review
Modelling introductions of MRSA to a hospital
- Increasing the detection rate reduces the endemic prevalence
- Effectiveness of intervention can depend critically on timing (the earlier the better)
- Isolation policies scale with MRSA reservoir or may fail
- Ability of MRSA strain to persist in, and transfer between, patients can be key factors in the long-term dynamics

Community acquired MRSA would have a MAJOR effect on the dynamics

Seven non RCT Studies where antiseptic use could be related to reductions in ICU MRSA
Edgeworth J, J Ant Chemother 2011:66;Suppl 2:i41-i47

<table>
<thead>
<tr>
<th>Reference</th>
<th>Setting</th>
<th>Outcome</th>
<th>Preventive intervention</th>
<th>Isolation</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>ICU</td>
<td>MRSA</td>
<td>Alcohol rub</td>
<td>No</td>
<td>None</td>
</tr>
<tr>
<td>B</td>
<td>ICU</td>
<td>MRSA</td>
<td>Chlorhexidine</td>
<td>No</td>
<td>None</td>
</tr>
<tr>
<td>C</td>
<td>ICU</td>
<td>MRSA</td>
<td>Both</td>
<td>No</td>
<td>None</td>
</tr>
<tr>
<td>D</td>
<td>ICU</td>
<td>MRSA</td>
<td>Neither</td>
<td>No</td>
<td>None</td>
</tr>
<tr>
<td>E</td>
<td>ICU</td>
<td>MRSA</td>
<td>Both</td>
<td>Yes</td>
<td>Isolation</td>
</tr>
<tr>
<td>F</td>
<td>ICU</td>
<td>MRSA</td>
<td>Both</td>
<td>Yes</td>
<td>Isolation</td>
</tr>
<tr>
<td>G</td>
<td>ICU</td>
<td>MRSA</td>
<td>Both</td>
<td>Yes</td>
<td>Isolation</td>
</tr>
</tbody>
</table>

4 used for Colonised
3 used for All

ICU MRSA Prevention and Control Strategies
- 12 strategies for Screening + Isolation
- 9 strategies for Screening + Decolonisation
- Sensitivity analyses for cost effectiveness (i.e. reality checks)
- Decolonisation key component of cost effective control strategies
- Warned about viability risks e.g. issues with resistance
- Further research needed e.g. no ICU RCTs

Targeted versus Universal Decolonization to Prevent ICU Infection
- Cluster RCT in 43 mainly community hospitals in 16 USA States with ICUs with SINGLE BEDDED ROOMS to one of 3 arms
  ARM 1: Active detection (nasal only) + ISOLATION if MRSA positive
  ARM 2: “+” + DECOLONISATION
    (5d nas. b.d. Mupirocin + Chlorhex bath)
  ARM 3: Universal DECOLONISATION with no screening
    3≥2 “>1” significant reductions in clinical MRSA and other pathogen BSIs but not MRSA BSIs
  CNS comprised significant proportion of BSIs and mainly in ARM 3 as had ≥1 Bone Marrow and Solid Organ Transplant. ICUs
Universal MRSA Screening – Is it Worthwhile, and For Whom
Dr. Barry Cookson, University College of London
A Webber Training Teleclass

Points of interest: Huang et al, 2013 Study
• ARM 3 had far fewer patients with no history of MRSA: might explain the lack of MRSA BSI effects?
• “Failed to look for antiseptic resistance”: lengths of stay were short (~3 days) but emphasised a risk and need surveillance
• No information on turnaround times/how screened/cost evaluations
• Only contact isolation when knew MRSA positive
  BUT
All in single rooms so less prone to cross infection….so impact of this was less?


General Wards: isolation and decolonisation are effective: Wesby et al, 2013
• General London Teaching Hospital wards 2006–2007
• Prospective MRSA surveillance 14,035 patient episodes and data informed stochastic modelling
• Undetected MRSA-positive patients source of 75% (67-86) of transmission events.
• 64% (95% CI 37-79) reduction by Isolation + Decolonization
  • Relative importance of each unclear

Outline
1. Types of Screening:
   Focus on Admission Screening
2. Effectiveness of measures it informs?
3. Who are the Stakeholders?
4. Review of studies
5. Conclusions

Hosted by Paul Webber  paul@webbertraining.com
www.webbertraining.com
Universal MRSA Screening – Is it Worthwhile, and For Whom
Dr. Barry Cookson, University College of London
A Webber Training Teleclass

Who are the Stakeholders?
- Managers and other Healthcare workers
  - Public and Private Sector
  - Infection Control
  - Others
- Patients, Families and their Advocates
- Innovation Landscape: Industry, Rapid Review Panel…
- Politicians, Policy Makers, DH
  - Electorate: difficult to review decisions especially before an election: can be seen as weakness
  - Treasury: all decisions need in depth review
  - Do criteria exist for cost effectiveness? England range of “120k to 120k QALY”

Patient Experience
Healthcare Associated Infection (HAI)
- Insufficient or incorrect understanding of the transmission, treatment and outcomes of HAI
- Exaggerated sense of HAI risk (Gould et al, 2009)
- and of MRSA (Brady et al., 2009, Easton et al., 2007, MORI POLL, 2010).
- Provided verbally no written information (Burnett et al., 2010, MORI Pol, 2010).

Scottish Pathfinder 2011:
Staff & Patient Views on Universal MRSA Screening
- ~700 individuals: few patients with direct experience
- Highly acceptable to patients, visitors & wider community
- Staff: “significant minority” more negative attitudes
  - Unacceptable; isolation facilities lacking, increased workload, screening/decolonisation protocol variation
  - All patients MRSA positive to be examined more fully.
  - All wards MRSA infected patients must be nursed in isolation not with other colonised patients.
  - English studies should be published soon (Loveday & Pellowe…)

Outline
1. Types of Screening:
   Focus on Admission Screening
2. Effectiveness of measures it informs?
3. Who are the Stakeholders?
4. Review of studies
5. Conclusions

English Quarterly Mandatory MRSA Bloodstream Infection Data
Mandatory Screening based on ~2007 data: Electives 4/2009
Emergencies 12/2010

Implications for low prevalence on MRSA Screening Otert et al, J. Hosp. Infect 2013;83: 114-121
London Teaching hospitals
- 2004-05: emergency admissions: 8.6%
- 2006-07: medical and surgical patients 6.7%
- 2008-09: London teaching hosp. : 28,892 admissions 1200 beds
  - Overall typical MRSA 2% rates
  - Previously unknown MRSA: 1.4% (were i.e. VERY LOW)

Hosted by Paul Webber  paul@webbertraining.com
www.webbertraining.com
Universal MRSA Screening – Is it Worthwhile, and For Whom
Dr. Barry Cookson, University College of London
A Webber Training Teleclass

Implications for low prevalence & CAMRSA on MRSA Screening Otter et al, 2013

2008-09: 2% MRSA
- Most were HAI MRSA (EMRSA-15 and –16)
- 18% of all isolates were community acquired MRSA (CA-MRSA)
  - 37.5% from accident and emergency
  - 23.1% from surgery
- Significantly different risk factors used e.g. antibiotics, international travel, overcrowding e.g. prisons, sport...

Concluded:
1) Low rate HAI-MRSA 2) Inconsistent recognition of CA-MRSA so HAI risk-factor-based screening strategies may be less effective?
2) Universal MRSA admission screening costings need to take account of this changing local epidemiology

Possible Strategies for Admission Screening

- Clinical Risk Based
- “Universal” (Mandatory or Otherwise)

Clinical Risk Based Assessment
(Yellow Pathfinder Method)

- Informed by National Evidence Based Guidelines
- Adapted for Local Use e.g.
  - Age; Previous colonisation; Antibiotics in previous year;
  - Diabetes; Chronic Lung Disease
  - Specialty admitted to e.g. Intensive Care Unit
  - Previous Hospital Admission
  - Breaks in integument e.g. Pressure Sores or other Wounds
  - Presence of devices e.g. Venous, Intubation, Urinary
  - Admission not from home e.g. Long Term Care Facility
  - Healthcare Worker or Family member of patient
  - Contact with pigs e.g. Denmark, Netherlands

Universal Screening

- Patients with risk factors might otherwise be missed?
- Patients with MRSA do not have risk factors
- “KISS” staff can follow it more easily so don’t forget
- It is argued that it is cost effective (at 6% rate!)

- Danger false sense of security in healthcare workers
  - Might assume patients are screened and not check notes or take a history!
  - In “NOW” study 19% of admissions were missed

Targeted versus universal screening and decolonization to reduce healthcare-associated meticillin-resistant Staphylococcus aureus infection

S.R. Deeny,*; R.S. Cooper,*; B. Cookson*; S. Hopkins*;*; J.V. Robotham*  
J Hosp Infect. 2013, 33-44

- Stochastic, individual-based model of MRSA transmission
- First one to include detailed patient movements between general medical and intensive care unit (ICU) wards, and between the hospital and community
- 18 months of individual patient data from a 900-bed London tertiary care hospital

Universal versus Targeted MRSA Screening?
Deeny et al, JHI 2013

- Compared universal screening and decolonisation with targeted screening of elderly care, ICU and re-admitted MRSA patients (All <1% MRSA colonisation) and decolonisation of positives
- Reduced screening and decolonization by ~95%
- Only 12% less reduction in infections than universal screening
- More efficient use of resources
- Less potential for resistance to antiseptics

Hosted by Paul Webber  paul@webbertraining.com  www.webbertraining.com
Universal MRSA Screening – Is it Worthwhile, and For Whom
Dr. Barry Cookson, University College of London
A Webber Training Teleclass

Evaluation of screening risk and non-risk patients for methicillin-resistant Staphylococcus aureus on admission in an acute care hospital.

- Eire tertiary referral hospital (incl neurosurgery and renal/pancreas transplantation) non randomised prospective study
- Multi-faceted prospective intervention including patient and environmental sampling and assess for risk factors (RF) e.g. previous MRSA, chronic wounds
- Initial MRSA screening: 48 of 392 (5%: “endemic”) but declined over 3 years of study.
- MRSA patients positive: 4/340 (1%) no recognized RF
  44/552 (8%) with RF
- Best strategy: Selective screening of RF positives; 2-4 cheaper

<table>
<thead>
<tr>
<th>Ministry of Health et al, 2008</th>
<th>London, UK</th>
<th>General Wards; Cross Over</th>
<th>Commercial PCR admission &amp; discharge</th>
<th>NSD in acquisitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harries et al, 2010</td>
<td>Birmingham UK</td>
<td>Surgical Wards; Cross Over</td>
<td>Commercial PCR admission &amp; discharge</td>
<td>Less MRSA acquired</td>
</tr>
<tr>
<td>Robinow et al, 2008</td>
<td>Chicago, USA</td>
<td>ICU &amp; Whole Hospital; Sequential ITS</td>
<td>Commercial PCR admission</td>
<td>Reduced MRSA infections. Acquisition?</td>
</tr>
<tr>
<td>Harbarth et al, 2008</td>
<td>Geneva, Switzerland</td>
<td>Surgical Wards; Cross Over</td>
<td>In-House PCR admission</td>
<td>NSD in MRSA infections. Acquisition?</td>
</tr>
</tbody>
</table>

PCR Testing: Additional Points
Harbarth et al, JAMA 2008:299: 1149-1157:
- Pragmatic study using an in-house PCR
- Median time from PCR-based admission screening to notification of test results was long (22.5 hours)
- Emergencies and laboratory delays: 120/386 (31%) MRSA carriers identified only after surgical intervention

Read other papers carefully
- What was the role of funded staff or the study design: include ensuring specimens were taken and results sent to ward and interventions implemented?
- Can you implement PCR effectively in the “real world”... and at what cost?

Cost-effectiveness of universal MRSA screening on admission to surgery
Murthy et al, CMI, 2011:16; 1747-1753

Modelled Harbarth et al, JAMA 2008:299: 1149-1157 study data and found:
- PCR is cost effective at their MRSA endemic admission rate
- If rate falls less effective than risk-based isolation and culture screening
- Ineffectiveness perhaps due to ongoing transmission whilst awaiting results?

- Bedside testing may be a way forward?
- Local analysis and decision making is required

Comparison of strategies to reduce methicillin-resistant Staphylococcus aureus rates in surgical patients: a controlled multicentre intervention trial
Lee et al, 2013 doi 10.1136/bmjopen-2013-0031

- Pragmatic ITS Cohort Study: 33 Surgical wards; 10 hospitals in 9 EU countries plus Israel
- All low incidence MRSA hospitals (0.8 to 1.1%)
- ARM 1: matched hand hygiene (HH) intervention: no reductions in MRSA but compliance already ~50%.
No attempt to change isolation/decolonisation practices.
- ARM 2: Universal MRSA screening (no pre-emptive isolation) and decolonisation if +; reduced MRSA cultures (15%/month) & infections (17%/m) on clean surgery wards

Surgical MRSA Study
Lee et al, 2013 doi 10.1136/bmjopen-2013-003126

- ARM 3: 2 countries used targeted risk factor screening (as mandated) and WHO HH; reduced MRSA cultures (12% /m: 95% CI 0.79 to 0.98 and 15%/m in clean surgery).
- No attempt was made to explore cost effectiveness of the interventions

Hosted by Paul Webber  paul@webbertraining.com  www.webbertraining.com
Universal MRSA Screening – Is it Worthwhile, and For Whom
Dr. Barry Cookson, University College of London
A Webber Training Teleclass

NHS Scotland Pathfinder Results: February 2011

http://www.demon.co.uk/ucol.ac.uk/harmo-screening/pathfinder_programmes/scotland/pathfinder
results-2011-02-21.pdf

- 6 acute hospitals: 81,438 admissions (30% elective & 70% emergency). About same no. as a London Teaching hospital
- MRSA colonisation prevalence fell: 5.5% to 3.5% in year
- Emergency rate 4.5% and elective admissions 2.1%
- 7.5 Infections per 1,000 patient days: reduced in the year
* Google search names: “Scotland MRSA Pathfinder”

Modelling: most clinically & cost effective strategy for a national MRSA screening policy

- Needs further work before recommending implemented
- Option “1”: Universal screening
- Option “2”*: Clinical Risk assessment (see previous slide) & targeted MRSA laboratory testing of at risk patients
- Option “3”: “2” Plus “universal” testing of selected specialties.
- Option 2 & 3: Similar Clinical Effectiveness
- Option “1” times the cost of “2” and twice cost of “3”
- Option “2” had greatest clinical impact with lowest cost

Pathfinder: Summary of Recommendations

- No point screening unless informs interventions quickly and effectively: look at bed management
- Side rooms were few but did not consider cohorting
- Median 3d stay so cannot Decolonise/Suppress/Isolate!
- Clinical risk assessment realistic alternative to universal screening (as effective and cheaper)
- Faster PCR testing may help; more costly and limited evidence of added benefit: alludes to false positives
- Consider bed-side or nearer point of care testing: recommends more work is done

DoH Audit of Universal MRSA Screening the “NOW” Study: 2010

Aims: Review implementation, impact on patient management, admission prevalence and extra yield of Universal MRSA Screening compared to
- “high-risk” specialty (IHS) cardiothoracic, vascular, orthopaedic .... or ..... 
- “Checklist-Activated” MRSA risk factor Screening (CLAS)

NOW Results*

1) Audit: Fuller et al. PLoS ONE 8(9): e74219
- Implementation of universal screening was poor
- Admission Screening performed on:
  - Emergency admissions 61% (median 67.3%),
  - Electives 81% (median 59.4%)
- Very low MRSA admission prevalence:
  - Emergencies 1%; Electives 0.6%
  - Inpatient. MRSA prevalence 3.3%
2) Modelling http://idrn.org/audit.php
- Preliminary results further analyses underway.

NOW Modelling: Conclusions (for England)

- High Risk Specialty, not Universal, screening is more cost effective BECAUSE it reduces MOST infections and deaths (rather than transmissions)
- Robust to prevalence: e.g. the same if doubled, transmission rates and no of death assumptions
- Uncertainties: mainly on isolation and decolonisation effectiveness: need more data!
- Current resources better spent: on improving intervention compliance e.g. faster results, ensuring ward interventions implemented e.g. isolation and, perhaps, decolonisation, sustaining improved infection prevention/control compliance e.g. hand hygiene, RF screening, isolation?

Hosted by Paul Webber  paul@webbertraining.com
www.webbertraining.com
Conclusions

- Literature supports universal screening is not likely to be cost effective (little detailed costings data)
- Policy decisions need to be fully discussed with all stakeholders
- Bedside testing may alter the rubric depending on cost evaluations (caution ref “DNA” testing future-proofing)
- Isolation and Bed Management need to be considered
- Decolonisation: there are now better studies supporting its role. BLT® antiseptic resistance surveillance needed
- Consider national and local context ref applicability of previous and current study results
- Modelling can inform decision making: needs good data!
- More work needed on cost effectiveness: essential for policy makers: need to show investment saves money!